ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905

Also written as “QLS31905” and “QLS31905 for Injection”.

Its studies are mostly in Pancreatic Neoplasms · Biliary Tract Neoplasms · Adenocarcinoma, led by Qilu Pharmaceutical.

Drug pageAnti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 13, 20256 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical65 open or runningphase 3since Jul 13, 2025Feb 23, 2022Dec 2026phase 2 · NCT06942767

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05278832 · 104 enrolled · China
  2. Jun 1, 2024Phase 2 study in Advanced Solid TumorNCT06446388 · 360 planned · China
  3. Apr 17, 2025Phase 2 study in AdenocarcinomaNCT06942767 · 100 planned
  4. Jul 13, 2025Phase 3 study in Pancreatic NeoplasmsNCT07079228 · 602 planned · China
  5. Aug 25, 2025Phase 2 study in CLDN18.2-positive Advanced Biliary Tract CancerNCT07151872 · 120 planned
  6. Jul 16, 2026Phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07716449 · 560 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in AdenocarcinomaNCT06942767
  2. Sep 2028Primary completion: phase 3 study in Gastric or Gastroesophageal Junction AdenocarcinomaNCT07716449
  3. Dec 2028Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07079228

TargetBeta

CD3E →CLDN18 →read by rule
“A bispecific antibody directed against the tumor-associated antigen (TAA) Claudin18.2 (CLDN18.2; A2 isoform of claudin-18) and the human T-cell surface antigen CD3, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
emaretamigruleAstellas Pharmaphase 33
Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863AstraZenecaphase 21

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07716449Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingSep 2028560
NCT07151872CLDN18.2-positive Advanced Biliary Tract Cancer2Not yet recruitingOct 2026120
NCT07079228Pancreatic Neoplasms · China3RecruitingDec 2028602
NCT06942767Adenocarcinoma2Not yet recruitingDec 2026100
NCT06446388Advanced Solid Tumor · China2Not yet recruitingJun 30, 2026360
NCT05278832Advanced Solid Tumors · China1UNKNOWNDec 31, 2022104

How it is read

Names in the registry

  • “QLS31905”, 4 entries
  • “QLS31905 for Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.